Suchergebnisse - "Melanoma/mortality [MeSH]"

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Autoren: Jonathan S. Zager Marlana Orloff Pier Francesco Ferrucci et al.

Quelle: Ann Surg Oncol

Schlagwörter: Male, Uveal Neoplasms, Adult, Aged, 80 and over, Liver Neoplasms, Middle Aged, Prognosis, Female [MeSH], Follow-Up Studies [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Adult [MeSH], Humans [MeSH], Drug Delivery Systems [MeSH], Melanoma/secondary [MeSH], Uveal Neoplasms/drug therapy [MeSH], Melphalan/administration, Antineoplastic Agents, Alkylating/therapeutic use [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Survival Rate [MeSH], Male [MeSH], Liver Neoplasms/secondary [MeSH], Melanoma/pathology [MeSH], Prognosis [MeSH], Antineoplastic Agents, Alkylating/administration, Hepatobiliary Tumors, Uveal Neoplasms/pathology [MeSH], Melanoma/drug therapy [MeSH], Liver Neoplasms/drug therapy [MeSH], Uveal Neoplasms/mortality [MeSH], Survival Rate, 03 medical and health sciences, Drug Delivery Systems, 0302 clinical medicine, Uveal Melanoma, Humans, Female, Melanoma, Melphalan, Antineoplastic Agents, Alkylating, Aged, Follow-Up Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38704501
https://repository.publisso.de/resource/frl:6504059

Comprehensive analysis of aberrantly methylated differentially expressed genes and validation of CDC6 in melanoma

Autoren: Liao, Li Han, Wei Shen, Yue et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: 0301 basic medicine, 0303 health sciences, Skin Neoplasms, Research, Gene Expression Profiling, Nuclear Proteins, Cell Cycle Proteins, DNA Methylation, Prognosis, Gene Expression Regulation, Neoplastic, 03 medical and health sciences, Melanoma, Cutaneous Malignant, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic [MeSH], Melanoma, Cutaneous Malignant [MeSH], Biomarkers, Female [MeSH], CDC6, Cell Cycle Proteins/genetics [MeSH], Melanoma/genetics [MeSH], Humans [MeSH], Protein Interaction Maps/genetics [MeSH], Skin Neoplasms/pathology [MeSH], Metastatic, Melanoma/mortality [MeSH], Skin Neoplasms/genetics [MeSH], DNA Methylation [MeSH], Melanoma/pathology [MeSH], Biomarkers, Tumor/genetics [MeSH], Prognosis [MeSH], Cell Cycle Proteins/metabolism [MeSH], DNA methylation, SKCM, Gene Expression Profiling [MeSH], Nuclear Proteins [MeSH], Humans, Female, Protein Interaction Maps, Melanoma

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39052109
https://repository.publisso.de/resource/frl:6501142

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Autoren: A. Gawaz I. Wolff L. Nanz et al.

Quelle: Cancer Immunol Immunother

Schlagwörter: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

Autoren: Miriam Mengoni Andreas Dominik Braun Mattes Simon Hinnerichs et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Middle Aged, Prognosis, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Body Composition, Humans, Female, Muscle, Skeletal, Tomography, X-Ray Computed, Melanoma, Immune Checkpoint Inhibitors, Melanoma/therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Muscle, Skeletal/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Low skeletal muscle mass, Tomography, X-Ray Computed [MeSH], Male [MeSH], Muscle, Skeletal/pathology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Body Composition [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Immunotherapy, Prognosis [MeSH], Skin Neoplasms/mortality [MeSH], Body composition, Retrospective Studies, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38796605
https://repository.publisso.de/resource/frl:6492801

Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA

Autoren: C. Posch Christian Diehl Bernhard Meyer et al.

Quelle: Clin Transl Oncol
Clin. Transl. Oncol. 23, 2020-2029 (2021)

Schlagwörter: Adult, Aged, 80 and over, Male, Proto-Oncogene Proteins B-raf, Brain Neoplasms, Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Proto-Oncogene Proteins B-raf/genetics [MeSH], GPA, Radiosurgery, Prognostic factors, Radiosurgery/methods [MeSH], Radiosurgery/adverse effects [MeSH], Brain metastases, Melanoma/diagnostic imaging [MeSH], Male [MeSH], Brain Neoplasms/mortality [MeSH], Research Article, Karnofsky Performance Status [MeSH], Female [MeSH], Brain Neoplasms/radiotherapy [MeSH], Follow-Up Studies [MeSH], Mutation [MeSH], Brain Neoplasms/secondary [MeSH], Adult [MeSH], Humans [MeSH], Melanoma/secondary [MeSH], Treatment Outcome [MeSH], Melanoma/radiotherapy [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], SRS, Prognosis [MeSH], Radiotherapy Dosage [MeSH], Brain Neoplasms/diagnostic imaging [MeSH], Radiotherapy Dosage, Middle Aged, Prognosis, ddc, Brain Metastases, Gpa, Prognostic Factors, Srs, 3. Good health, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Mutation, Humans, Female, Karnofsky Performance Status, Aged, Follow-Up Studies, Retrospective Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s12094-021-02607-8.pdf
https://pubmed.ncbi.nlm.nih.gov/33993415
https://link.springer.com/article/10.1007/s12094-021-02607-8
https://pubmed.ncbi.nlm.nih.gov/33993415/
https://dialnet.unirioja.es/servlet/articulo?codigo=8062060
https://link.springer.com/content/pdf/10.1007/s12094-021-02607-8.pdf
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62109
https://repository.publisso.de/resource/frl:6445606
https://mediatum.ub.tum.de/doc/1624398/document.pdf

Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma

Autoren: Laura Susok Thilo Gambichler

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Adult, Male, Skin Neoplasms, Adolescent, Original Article – Clinical Oncology, White People, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Germany, Humans, 10. No inequality, Melanoma, Aged, 80 and over [MeSH], Aged [MeSH], Skin Neoplasms/ethnology [MeSH], Whites/statistics, Extremities/pathology [MeSH], Germany/epidemiology [MeSH], Cohort Studies [MeSH], Neoplasm Staging [MeSH], Male [MeSH], Melanoma/pathology [MeSH], Superficial spreading melanoma, Case-Control Studies [MeSH], Progosis, Melanoma/diagnosis [MeSH], Adolescent [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Humans [MeSH], Overall survival, Survival Analysis [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Prognosis [MeSH], Young Adult [MeSH], Skin Neoplasms/mortality [MeSH], Acral lentiginous melanoma, Melanoma/ethnology [MeSH], Skin Neoplasms/diagnosis [MeSH], Aged, Neoplasm Staging, Aged, 80 and over, ddc:610, Extremities, Middle Aged, Prognosis, Survival Analysis, 3. Good health, Case-Control Studies, Female, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03630-6.pdf
https://pubmed.ncbi.nlm.nih.gov/33856527
https://link.springer.com/article/10.1007/s00432-021-03630-6
https://www.ncbi.nlm.nih.gov/pubmed/33856527
http://europepmc.org/article/MED/33856527
https://link.springer.com/content/pdf/10.1007/s00432-021-03630-6.pdf
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/9784
https://nbn-resolving.org/urn:nbn:de:hbz:294-97841
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/9784/GambichlerThilo15042021.pdf
https://repository.publisso.de/resource/frl:6449884

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

Autoren: Torsten Pietsch Jennifer Landsberg Glen Kristiansen et al.

Quelle: Cancer Immunol Immunother

Schlagwörter: Research Report, Adult, Male, 0301 basic medicine, 03 medical and health sciences, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic [MeSH], CTLA-4, Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Male [MeSH], Melanoma/pathology [MeSH], DNA methylation, Melanoma/drug therapy [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Predictive biomarker, Ipilimumab/therapeutic use [MeSH], Survival Rate [MeSH], CTLA-4 Antigen/genetics [MeSH], DNA Methylation [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Biomarkers, Tumor/genetics [MeSH], Immunotherapy, Prognosis [MeSH], Promoter Regions, Genetic [MeSH], Humans, CTLA-4 Antigen, Promoter Regions, Genetic, 10. No inequality, Aged, Retrospective Studies, Aged, 80 and over, 0303 health sciences, DNA Methylation, Middle Aged, Prognosis, Ipilimumab, ddc, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, Female, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00262-020-02777-4.pdf
https://pubmed.ncbi.nlm.nih.gov/33196890
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139923
https://www.scilit.net/article/a6bc7ad018f132d9f73a17b642cf4466?action=show-references
https://link.springer.com/content/pdf/10.1007/s00262-020-02777-4.pdf
https://www.ncbi.nlm.nih.gov/pubmed/33196890
https://pubmed.ncbi.nlm.nih.gov/33196890/
https://link.springer.com/article/10.1007/s00262-020-02777-4
https://repository.publisso.de/resource/frl:6470084
https://mediatum.ub.tum.de/doc/1624233/document.pdf

Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

Autoren: Patrick Schummer Bastian Schilling Anja Gesierich

Quelle: Am J Clin Dermatol

Schlagwörter: Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins B-raf, ddc:610, Skin Neoplasms, Time Factors, Review Article, Progression-Free Survival, 3. Good health, Survival Rate, 03 medical and health sciences, 0302 clinical medicine, Proto-Oncogene Proteins B-raf/genetics [MeSH], Progression-Free Survival [MeSH], Gain of Function Mutation [MeSH], Skin Neoplasms/drug therapy [MeSH], Dermatology, Neoplasm Staging [MeSH], Melanoma/drug therapy [MeSH], Pharmacotherapy, Melanoma/diagnosis [MeSH], Proto-Oncogene Proteins B-raf/antagonists, Pharmacology/Toxicology, Melanoma/genetics [MeSH], Protein Kinase Inhibitors/pharmacology [MeSH], Humans [MeSH], Melanoma/mortality [MeSH], Protein Kinase Inhibitors/therapeutic use [MeSH], Time Factors [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Survival Rate [MeSH], Mitogen-Activated Protein Kinase Kinases/antagonists, Skin Neoplasms/genetics [MeSH], Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH], Skin Neoplasms/mortality [MeSH], Skin Neoplasms/diagnosis [MeSH], Immune Checkpoint Inhibitors/pharmacology [MeSH], Gain of Function Mutation, Antineoplastic Combined Chemotherapy Protocols, Humans, Immune Checkpoint Inhibitors, Melanoma, Protein Kinase Inhibitors, Neoplasm Staging

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s40257-020-00509-z.pdf
https://pubmed.ncbi.nlm.nih.gov/32124332
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371660
https://pubmed.ncbi.nlm.nih.gov/32124332/
https://link.springer.com/article/10.1007/s40257-020-00509-z
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371660
https://europepmc.org/article/MED/32124332
https://link.springer.com/content/pdf/10.1007/s40257-020-00509-z.pdf
https://repository.publisso.de/resource/frl:6465103
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/23481
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-234818
https://doi.org/10.1007/s40257-020-00509-z
https://opus.bibliothek.uni-wuerzburg.de/files/23481/40257_2020_Article_509.pdf

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Autoren: Anne Fröhlich Dennis Niebel Simon Fietz et al.

Quelle: Cancer Immunol Immunother

Schlagwörter: Adult, Male, 0301 basic medicine, Melanoma/therapy [MeSH], Costimulatory and Inhibitory T-Cell Receptors/antagonists, Disease Progression [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents, Immunological/pharmacology [MeSH], Advanced melanoma, Oncolytic Virotherapy/methods [MeSH], Original Article, Neoplasm Staging [MeSH], Immunotherapy/methods [MeSH], Male [MeSH], Melanoma/pathology [MeSH], Targeted therapy, Skin Neoplasms/immunology [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Drug Resistance, Neoplasm/drug effects [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Drug Resistance, Neoplasm/immunology [MeSH], Melanoma/mortality [MeSH], Herpesvirus 1, Human [MeSH], Melanoma/immunology [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Biological Products/administration, Immunotherapy, Skin Neoplasms/mortality [MeSH], Skin Neoplasms/therapy [MeSH], Talimogene laherparepvec, Costimulatory and Inhibitory T-Cell Receptors/immunology [MeSH], Acquired resistance, Herpesvirus 1, Human, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Costimulatory and Inhibitory T-Cell Receptors, Humans, Melanoma, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Oncolytic Virotherapy, Biological Products, Middle Aged, Progression-Free Survival, 3. Good health, Drug Resistance, Neoplasm, Disease Progression, Female, Follow-Up Studies

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00262-020-02487-x.pdf
https://pubmed.ncbi.nlm.nih.gov/32052079
https://link.springer.com/content/pdf/10.1007/s00262-020-02487-x.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503
https://pubmed.ncbi.nlm.nih.gov/32052079/
https://link.springer.com/article/10.1007/s00262-020-02487-x
https://www.ncbi.nlm.nih.gov/pubmed/32052079
https://repository.publisso.de/resource/frl:6470336

Types of second primary cancer influence overall survival in cutaneous melanoma

Autoren: Zheng, Guoqiao Chattopadhyay, Subhayan Sundquist, Kristina et al.

Quelle: http://lobid.org/resources/99370673697106441#!, 21(1):1123.

Schlagwörter: Cancer Survivors/statistics, Female [MeSH], Independent primary, Age Factors [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Second melanoma, Neoplasms, Second Primary/mortality [MeSH], Overall survival, Middle Aged [MeSH], Prognosis, Melanoma/mortality [MeSH], Time Factors [MeSH], Smoking [MeSH], Proportional Hazards Models [MeSH], Male [MeSH], Time-dependent analysis, Research, Skin Neoplasms/mortality [MeSH], Sweden/epidemiology [MeSH], Sex Factors [MeSH], Registries [MeSH]

Relation: https://repository.publisso.de/resource/frl:6463197; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524825/

Verfügbarkeit: https://repository.publisso.de/resource/frl:6463197
https://doi.org/10.1186/s12885-021-08845-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524825/